-
Your concerns
Our articles to help you gain a better understanding
-
Our solutions
-
DUCRAY Dermatological Laboratories
Treats and limits the recurrence of eczema lesions. Tested under dermatological control.
Medical device
Treats eczema lesions - Soothes - Soothes itchiness - Decongests
A medical device that treats atopic or contact eczema on the eyelids.
DEXYANE MeD Palpebral is a medical device* for treating localised atopic or contact eczema on the eyelids.
Its formula, specially adapted to respect the delicate skin of the eyelids, acts as an ultra-hydrating dressing.
It instantly soothes itching sensations¹ and reduces burning sensations¹.
DEXYANE MeD Palpebral restores the skin barrier and corrects dryness.
It can be used as a stand-alone treatment, in combination with, or as a follow-up to topical corticosteroids.
Clinically proven effectiveness.
DEXYANE MeD Palpébral relieves inflammatory eczema lesions on the eyelids.
• SOOTHES itching
• COMFORTS immediately and decongests
• LIMITS the recurrence of eczema lesions
*DEXYANE MeD Palpebral is a medical device, a regulated health product which carries, in accordance with this regulation, the CE mark. Carefully read the instruction leaflet provided. Do not use if pregnant or breastfeeding. Avoid direct contact with the eyes. Age 3 months and up. Manufacturer : Pierre Fabre Medical Devices.
Biodegradable formula*
Formulated to limit the impact on the aquatic environment***
*According to a OECD 301 test or biodegradability index method
*** According to a OECD 301 test and CLP classification of the formula
Fully recyclable packaging
Manufactured and packaged in an environmentally certified facility****
****According to ISO 14001 and/or 50001
Product manufactured and packaged in a factory with high social standards
Ducray is a brand of the Pierre Fabre Group, certified at the highest Exemplary level of AFNOR Certification’s Committed to CSR and Responsibility Europe labels, thus consolidating a long-standing commitment to contributing to sustainable development. ...